Vandana Batra, MD Vandana Batra, MD, is an Attending Physician in the Cancer Center at Children’s Hospital of Philadelphia. Locations: Main Campus Appointments and Referrals: 1-800-TRY-CHOP (1-800-879-2467) Education and Training Medical SchoolMBBS - Lady Hardinge Medical College, New Delhi, India InternshipLady Hardinge Medical College and Hospital (LHMC), New Delhi, India ResidencyPediatrics - Children's Hospital of Michigan, Detroit, MI Pediatrics - Maulana Azad Medical College and Hospital (MAMC), Delhi, India FellowshipPediatric Hematology/Oncology - The Children's Hospital of Philadelphia, Philadelphia, PA Pediatric Hematology/Oncology - Children's Hospital of Los Angeles, Los Angeles, CA, USA Board CertificationGeneral PediatricsPediatric Hematology-OncologyPediatrics Titles and Academic Titles Attending PhysicianAssistant Professor of Clinical Pediatrics in Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania Conditions Treated Neuroblastoma Departments and Services Cancer CenterSolid Tumor Program Publications Papers2017 Hart LS, Rader J, Raman P, Batra V, Russell MR, Tsang M, Gagliardi M, Chen L, Martinez D, Li Y, Wood A, Kim S, Parasuraman S, Delach S, Cole KA, Krupa S, Boehm M, Peters M, Caponigro G, Maris JM. Preclinical therapeutic synergy of MEK1/2 and CDK4/6 inhibition in neuroblastoma. Clin Cancer Res. 2017;23(7):1785-1796. 2015 Armstrong AE, Weese-Mayer DE, Mian A, Maris JM, Batra V, Gosiengfiao Y, et al. Treatment of neuroblastoma in congenital central hypoventilation syndrome with a PHOX2B polyalanine repeat expansion mutation: New twist on a neurocristopathy syndrome. Pediatric blood & cancer. 2015 May 22. PubMed PMID: 26011159. 2013 Batra V, Sands SA, Holmes E, Geyer JR, Yates A, Becker L, et al. Long-term survival of children less than six years of age enrolled on the CCG-945 phase III trial for newly-diagnosed high-grade glioma: A report from the Children's Oncology Group. Pediatric blood & cancer. 2013 Aug 23. PubMed PMID: 24038913. Abstracts2017 Batra V et al Meta-[211At]astatobenzylguanidine ([211At]MABG) is a potent alpha particle emitting systemic targeted radiotherapeutic in preclinical models of neuroblastoma. AACR Annual Meeting, Washington, D.C.; April 2017. Welsh S, Rosenblatt S, Batra V, Betensky M, Ichord R, Himebauch A progressive malignant arterial ischemic stroke: A rare presentation of pediatric APL. Society for Critical Care Medicine conference. Hawaii; January 2017. 2016 Batra V et al Preclinical characterization of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma. Oral presentation at ANR Cairns, Australia June 2016. Huibregtse K, Vo K, Dubois S, Fetzko S, Batra V et al Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with 131Imetaiodobenzylguanidine Oral presentation (Huibregtse K) at ANR Cairns, Australia; June 2016 DuBois S, Mody R, Van Ryn C, Naranjo A, Kreissman S, Baker DL, Parisi M, Barry Shulkin B, Maris JM, Batra V et al Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG) Oral presentation (DuBois S) at ANR Cairns, Australia; June 2016. Batra V et al Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations J Nucl Med 2016 57:1787. Shulkin B, Maris JM, Batra V et al Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Children’s Oncology Group (COG). Meeting abstracts J Clin Oncol 34, 2016 (suppl; abstr 10526) ASCO Annual Meeting May 2016. 2015 Batra V et al Development of meta-[211At]astatobenzylguanidine ([211At]MABG) as an alpha particle emitting systemic targeted radiotherapeutic for neuroblastoma AACR Annual Meeting, Philadelphia PA April 2015 Hart L, Chen L, Batra V et al Combined MEK1/2 and PI3K Inhibition Induces Synergistic Caspase-Dependent Apoptosis in Neuroblastoma, AACR Annual Meeting, Philadelphia PA April 2015 2014 Chacko AM, Batra V et al Ultratrace meta-211At-astatobenzylguanidine (211At-MABG) for targeted radiotherapy of neuroendocrine cancer Journal of Nuclear Medicine Meeting abstracts May 2014; 55: 1075. Bhatia A, Batra V et al Soft Tissue Neuroblastoma Response to 131I-MIBG therapy in the Pediatric Population. Meeting abstracts Pediatric Radiology June 2014, Volume 44, Issue 2 Supplement, pp 255-402 BooksChapters Batra V, Deyell R, Maris JM chapter: Molecular oncology of neuroblastoma in Molecular Oncology: Causes of Cancer and Targets for Treatment Charles Sawyers, Frank Rauscher and Edward Gelmann (eds.). Cambridge University Press. Posters and Presentations2014 Hart L, Rader J, Raman P, Batra V et al Combined inhibition of CDK4/6 and MEK1/2 in preclinical models of neuroblastoma. Poster, ANR, Cologne, Germany, May 2014. Batra V et al Preclinical development of meta-[211At] astatobenzylguanidine ([211At] MABG) targeted radiotherapy for neuroblastoma. Poster, AACR Pediatric Oncology Conference November 2013, Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes and Poster Presentation at CHOP Poster day February 2014. 2013 Hart L, Batra V et al MEK 1/2 inhibition and biomarkers of response in preclinical models of neuroblastoma. Poster, AACR Pediatric Oncology Conference November 2013, Pediatric Cancer at the Crossroads: Translating Discovery into Improved Outcomes. Invited Lectures 2014 Rob Forrest Memorial Symposium on Medical Health Physics ‘Targeted Radiotherapy for the childhood cancer Neuroblastoma’ Thomas Jefferson University. December 2014 Awards and Honors 2016 Selected to attend the ASCO/AACR Methods in Clinical Cancer Research Workshop, Vail, CO 2015, Postdoctoral Research Award, CHOP Research Poster Day, Philadelphia, PA 2010, Selected to attend the Molecular Biology in Clinical Oncology Annual AACR Aspen Workshop, Aspen, CO 2004, Selected to attend the 13th Annual Workshop on Biostatistics and Trial Design, Brewster, MA 1995, Best Paper, Dr PN Taneja Award Indian Academy of Pediatrics 1993, Ranked in top 1% in Delhi University, India for MD entrance exam. 1991, Won the first Prize in the Dr S.K. Sen Inter Medical Debate Competition at Delhi Medical Association. 1990, Dr DN Mullick award for “Most meritorious student in clinical proficiency and excellence in Pediatrics”. 1990, First Prize in 4th Indian National Academy of Pediatrics: National Quiz. 1989, Mrs. Sharma memorial prize for the best student in microbiology. 1989, First in Class (1st/200), Microbiology, IV year MBBS. 1987, Mary Pickford award for the Best student in Anatomy dissection. Leadership and Memberships Memberships in Professional Organizations American Association for Cancer Research American Academy of Pediatrics American Society of Pediatric Hematology Oncology American Society of Clinical Oncology Children’s Oncology Group Advances in Neuroblastoma Patient Experience Ratings About the Patient Experience Rating System The Patient Experience Rating is an average of all responses to the care provider related questions shown above from our nationally-recognized Press Ganey Patient Satisfaction Survey. Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question. Responses are measured on a scale of 1 to 5 with 5 being the best score. We are committed to true transparency. However, to ensure the comments are fair and correctly attributed, we review each one before posting to the website. We exclude entire comments that disclose patient's protected health information, are off-topic, or include other confidential or inappropriate content. Comments will appear on provider bios only if providers have a minimum number of comments. Comments are shared internally for education purposes to ensure that we are doing our very best for the patients and families for whom we are privileged to care. The comments are submitted by patients and families and reflect their views and opinions. The comments are not endorsed by and do not reflect the views of Children’s Hospital of Philadelphia.